JP2019512550A5 - - Google Patents

Download PDF

Info

Publication number
JP2019512550A5
JP2019512550A5 JP2019500726A JP2019500726A JP2019512550A5 JP 2019512550 A5 JP2019512550 A5 JP 2019512550A5 JP 2019500726 A JP2019500726 A JP 2019500726A JP 2019500726 A JP2019500726 A JP 2019500726A JP 2019512550 A5 JP2019512550 A5 JP 2019512550A5
Authority
JP
Japan
Prior art keywords
group
pharmaceutically acceptable
acceptable salt
hydrate
cooh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019500726A
Other languages
English (en)
Japanese (ja)
Other versions
JP6790222B2 (ja
JP2019512550A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2017/078139 external-priority patent/WO2017162206A1/zh
Publication of JP2019512550A publication Critical patent/JP2019512550A/ja
Publication of JP2019512550A5 publication Critical patent/JP2019512550A5/ja
Application granted granted Critical
Publication of JP6790222B2 publication Critical patent/JP6790222B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019500726A 2016-03-25 2017-03-24 エストロゲン受容体ダウンレギュレーターとしての置換インドール化合物 Active JP6790222B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610180518 2016-03-25
CN201610180518.7 2016-03-25
CN201610867918.5 2016-09-29
CN201610867918 2016-09-29
PCT/CN2017/078139 WO2017162206A1 (zh) 2016-03-25 2017-03-24 作为雌激素受体降解剂的吲哚并取代哌啶类化合物

Publications (3)

Publication Number Publication Date
JP2019512550A JP2019512550A (ja) 2019-05-16
JP2019512550A5 true JP2019512550A5 (https=) 2019-11-28
JP6790222B2 JP6790222B2 (ja) 2020-11-25

Family

ID=59899253

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019500726A Active JP6790222B2 (ja) 2016-03-25 2017-03-24 エストロゲン受容体ダウンレギュレーターとしての置換インドール化合物

Country Status (11)

Country Link
US (1) US10519143B2 (https=)
EP (1) EP3434668B1 (https=)
JP (1) JP6790222B2 (https=)
KR (1) KR102111792B1 (https=)
CN (1) CN108884035B (https=)
AU (1) AU2017239348B2 (https=)
CA (1) CA3018801C (https=)
ES (1) ES2821407T3 (https=)
RU (1) RU2722441C2 (https=)
SG (1) SG11201808363TA (https=)
WO (1) WO2017162206A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019057201A1 (zh) * 2017-09-25 2019-03-28 罗欣生物科技(上海)有限公司 一种雌激素受体抑制剂的晶型及其制备方法
CA3109090A1 (en) 2018-08-17 2020-02-20 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for the treatment of breast cancer
CN113166056B (zh) * 2018-11-28 2024-07-05 罗欣药业(上海)有限公司 一种雌激素受体下调剂的盐型、晶型及其制备方法
JP7716980B2 (ja) * 2018-12-17 2025-08-01 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド エストロゲン受容体拮抗剤
CN116891461A (zh) * 2022-03-30 2023-10-17 罗欣药业(上海)有限公司 一种serd中间体的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
GB0917571D0 (en) * 2009-10-07 2009-11-25 Karobio Ab Novel estrogen receptor ligands
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
SG11201405918XA (en) * 2012-03-20 2014-10-30 Seragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
JP2017507964A (ja) * 2014-03-13 2017-03-23 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体モジュレーターを用いた治療的組合せ
CA2941161A1 (en) * 2014-03-13 2015-09-17 F.Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants

Similar Documents

Publication Publication Date Title
JP2019512550A5 (https=)
CN109311812A (zh) 作为c-MET抑制剂的吡啶酮类化合物
JP2008505194A5 (https=)
JP2012515219A5 (https=)
JP2019524883A5 (https=)
JP2016540742A5 (https=)
JP2018531218A5 (https=)
JP2016520618A5 (https=)
JP2017537940A5 (https=)
JP2005289914A5 (https=)
RU2018139801A (ru) Содержащее заместитель, представляющий собой бутан, в гетероциклическом кольце производное пиридона для лечения фиброза и воспалительных заболеваний
JP2017518281A5 (https=)
JP2016516699A5 (https=)
RU2019130519A (ru) 4-пиридоновое соединение или его соль, фармацевтическая композиция и содержащий их состав
JP2020507589A5 (https=)
RU2017131559A (ru) Замещенное производное 2н-пиразола
JP2016505637A5 (https=)
JP2013129675A5 (https=)
PE20140109A1 (es) Inhibidores del virus de la hepatitis c
JP2017536332A5 (https=)
JP2017523225A5 (https=)
JP2017538689A5 (https=)
JP2010504286A5 (https=)
RU2018135203A (ru) Замещённые индольные соединения в качестве понижающих регуляторов рецепторов эстрогена
JP2017519821A5 (https=)